IL263211B2 - Compositions and methods relating to engineered fc constructs - Google Patents

Compositions and methods relating to engineered fc constructs

Info

Publication number
IL263211B2
IL263211B2 IL263211A IL26321118A IL263211B2 IL 263211 B2 IL263211 B2 IL 263211B2 IL 263211 A IL263211 A IL 263211A IL 26321118 A IL26321118 A IL 26321118A IL 263211 B2 IL263211 B2 IL 263211B2
Authority
IL
Israel
Prior art keywords
domain
construct
amino acid
domain monomer
monomer
Prior art date
Application number
IL263211A
Other languages
English (en)
Hebrew (he)
Other versions
IL263211B1 (en
IL263211A (en
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of IL263211A publication Critical patent/IL263211A/en
Publication of IL263211B1 publication Critical patent/IL263211B1/en
Publication of IL263211B2 publication Critical patent/IL263211B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Prostheses (AREA)
IL263211A 2016-05-23 2017-05-23 Compositions and methods relating to engineered fc constructs IL263211B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662340322P 2016-05-23 2016-05-23
US201762443451P 2017-01-06 2017-01-06
PCT/US2017/034087 WO2017205436A1 (en) 2016-05-23 2017-05-23 Compositions and methods related to engineered fc constructs

Publications (3)

Publication Number Publication Date
IL263211A IL263211A (en) 2018-12-31
IL263211B1 IL263211B1 (en) 2023-05-01
IL263211B2 true IL263211B2 (en) 2023-09-01

Family

ID=60412547

Family Applications (3)

Application Number Title Priority Date Filing Date
IL263213A IL263213B2 (en) 2016-05-23 2017-05-23 Compositions and methods related to engineered fc constructs
IL309293A IL309293A (en) 2016-05-23 2017-05-23 Compositions and methods relating to engineered FC constructs
IL263211A IL263211B2 (en) 2016-05-23 2017-05-23 Compositions and methods relating to engineered fc constructs

Family Applications Before (2)

Application Number Title Priority Date Filing Date
IL263213A IL263213B2 (en) 2016-05-23 2017-05-23 Compositions and methods related to engineered fc constructs
IL309293A IL309293A (en) 2016-05-23 2017-05-23 Compositions and methods relating to engineered FC constructs

Country Status (15)

Country Link
US (4) US11155640B2 (OSRAM)
EP (2) EP3484514B1 (OSRAM)
JP (5) JP2019519527A (OSRAM)
KR (3) KR102635635B1 (OSRAM)
CN (4) CN116063540A (OSRAM)
AU (2) AU2017272109B2 (OSRAM)
BR (2) BR112018074056A2 (OSRAM)
CA (2) CA3025310A1 (OSRAM)
DK (1) DK3484514T3 (OSRAM)
ES (1) ES2973251T3 (OSRAM)
IL (3) IL263213B2 (OSRAM)
NZ (2) NZ749279A (OSRAM)
PL (1) PL3484514T3 (OSRAM)
SG (3) SG11201810465RA (OSRAM)
WO (2) WO2017205434A1 (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2962694T3 (es) 2014-05-02 2024-03-20 Momenta Pharmaceuticals Inc Composiciones y procedimientos relacionados con construcciones de Fc manipuladas
ES2972740T3 (es) 2016-03-02 2024-06-14 Momenta Pharmaceuticals Inc Procedimientos relacionados con construcciones de Fc modificadas genéticamente
IL263213B2 (en) * 2016-05-23 2024-05-01 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
EP3565588A4 (en) 2017-01-06 2020-12-16 Momenta Pharmaceuticals, Inc. COMPOSITIONS AND METHODS RELATING TO MODIFIED FC CONSTRUCTIONS
EP3820910A4 (en) * 2018-07-11 2022-06-22 Momenta Pharmaceuticals, Inc. COMPOSITIONS AND METHODS RELATING TO ENGINEERED FC ANTIGEN-BINDING DOMAIN CONSTRUCTS
MX2021000280A (es) * 2018-07-11 2021-11-12 Momenta Pharmaceuticals Inc Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente.
CA3106108A1 (en) * 2018-07-11 2020-01-16 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs targeted to pd-l1
MX2021000288A (es) * 2018-07-11 2021-09-08 Momenta Pharmaceuticals Inc Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente.
CN113194990A (zh) * 2018-07-11 2021-07-30 动量制药公司 与靶向CD38的工程化Fc-抗原结合结构域构建体有关的组合物和方法
MX2021000290A (es) * 2018-07-11 2021-09-08 Momenta Pharmaceuticals Inc Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente dirigidos a ccr4.
KR20210042326A (ko) * 2018-07-11 2021-04-19 모멘타 파머슈티컬스 인코포레이티드 조작된 Fc-항원 결합 도메인 작제물에 관련된 조성물 및 방법
CA3106207A1 (en) * 2018-07-11 2020-01-16 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ctla-4
KR102661494B1 (ko) 2019-03-08 2024-04-29 에이치엘만도 주식회사 랙구동형 동력 보조 조향장치
EP4028415A1 (en) 2019-09-13 2022-07-20 CSL Behring Lengnau AG Recombinant igg fc multimers for the treatment of immune complex-mediated kidney disorders
KR20220110818A (ko) 2019-12-06 2022-08-09 체에스엘 베링 렝나우 아게 Fc 다량체의 안정한 조성물
CN111808170A (zh) * 2020-06-29 2020-10-23 江苏为真生物医药技术股份有限公司 多肽、hla-dr蛋白及其制备方法和应用
CN117043190A (zh) * 2020-12-07 2023-11-10 因外泰克斯公司 延长治疗剂在家畜动物中的半衰期的组合物和使用方法
WO2024206820A1 (en) * 2023-03-30 2024-10-03 Dna Twopointo, Inc. Fc engineering for heterodimeric antibody format

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008151088A2 (en) * 2007-06-01 2008-12-11 University Of Maryland, Baltimore Immunoglobulin constant region fc receptor binding agents
WO2014031646A2 (en) * 2012-08-20 2014-02-27 Gliknik Inc. Molecules with antigen binding and polyvalent fc gamma receptor binding activity
WO2014060712A1 (en) * 2012-10-17 2014-04-24 Liverpool School Of Tropical Medicine Immunomodulatory proteins
WO2015168643A2 (en) * 2014-05-02 2015-11-05 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc constructs

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2556219B1 (fr) 1983-12-07 1987-06-26 Merieux Inst Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines
US5426641A (en) 1994-01-28 1995-06-20 Bell Communications Research, Inc. Adaptive class AB amplifier for TDMA wireless communications systems
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0975355A2 (en) 1996-06-14 2000-02-02 Smithkline Beecham Corporation Hexameric fusion proteins and uses therefor
US20090074839A1 (en) 1997-01-22 2009-03-19 Marton Milankovits Pharmaceutical Compositions Primarily for the Treatment and Prevention of Genitourinary Infections and their Extragenital Complications
US20020062010A1 (en) * 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US7951917B1 (en) * 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
JP2003518075A (ja) 1999-12-24 2003-06-03 ジェネンテック・インコーポレーテッド 生理活性化合物の消失半減期延長のための方法及び組成物
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
US8043829B2 (en) * 2006-10-25 2011-10-25 Amgen Inc. DNA encoding chimeric toxin peptide fusion proteins and vectors and mammalian cells for recombinant expression
BRPI0620639A2 (pt) 2006-12-21 2011-11-22 Micromet Ag anticorpos de cadeia simples biespecìficos e composição farmacêutica compreendendo os mesmos
CA2682605A1 (en) 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
CN101802197A (zh) 2007-05-14 2010-08-11 比奥根艾迪克Ma公司 单链FC（ScFc）区、包含其的结合多肽及与其相关的方法
ES2563027T3 (es) * 2008-01-07 2016-03-10 Amgen Inc. Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
DK2247304T3 (en) 2008-04-02 2016-09-26 Macrogenics Inc Her2 / neu-specific antibodies and methods of use thereof
WO2010042481A1 (en) 2008-10-06 2010-04-15 University Of Chicago Compositions and methods related to bacterial eap, emp, and/or adsa proteins
US20100143353A1 (en) 2008-12-04 2010-06-10 Mosser David M POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (lgG) AND METHODS OF USING THE SAME
EP2376105B1 (en) 2008-12-18 2015-07-29 Dana-Farber Cancer Institute, Inc. Nkg2d-fc for immunotherapy
CN102369291A (zh) 2009-01-23 2012-03-07 比奥根艾迪克Ma公司 效应子功能降低的稳定Fc多肽及使用方法
CA2762302A1 (en) 2009-05-20 2010-11-25 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
US20120064008A1 (en) 2009-05-20 2012-03-15 Bruce Zetter Compositions for the treatment of metastatic cancer and methods of use thereof
CA2766065C (en) 2009-06-30 2020-07-21 Research Development Foundation Immunoglobulin fc polypeptides
JP6091894B2 (ja) 2009-09-16 2017-03-15 ジェネンテック， インコーポレイテッド コイルドコイルおよび／またはテザー含有タンパク質複合体およびその使用
JP5898082B2 (ja) 2009-10-07 2016-04-06 マクロジェニクス，インコーポレーテッド フコシル化程度の変更により改良されたエフェクター機能を示すＦｃ領域含有ポリペプチドおよびその使用法
EP2504360B1 (en) 2009-11-23 2018-08-15 Amgen Inc. Monomeric antibody fc
GB0922209D0 (en) 2009-12-18 2010-02-03 Univ Nottingham Proteins, nucleic acid molecules and compositions
CN103124788B (zh) 2010-05-21 2016-01-13 梅里麦克制药股份有限公司 双特异性融合蛋白
AU2011274423B2 (en) 2010-07-09 2016-02-11 Bioverativ Therapeutics Inc. Chimeric clotting factors
EP2598533B1 (en) 2010-07-28 2019-02-20 Gliknik Inc. Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions
CA2808154A1 (en) 2010-08-13 2012-02-16 Medimmmune Limited Monomeric polypeptides comprising variant fc regions and methods of use
RU2604490C2 (ru) 2010-11-05 2016-12-10 Займворкс Инк. ДИЗАЙН УСТОЙЧИВОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В Fc ДОМЕНЕ
HUE033205T2 (en) * 2010-12-23 2017-11-28 Janssen Biotech Inc Active protease-resistant antibody fc mutants
WO2012123949A1 (en) 2011-03-17 2012-09-20 Ramot At Tel-Aviv University Ltd. Bi- and monospecific, asymmetric antibodies and methods of generating the same
EA201791693A1 (ru) 2011-03-25 2018-05-31 Гленмарк Фармасьютикалс С.А. Гетеродимерные иммуноглобулины
EP2773671B1 (en) * 2011-11-04 2021-09-15 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
EP3693000B1 (en) 2012-06-08 2022-03-02 Bioverativ Therapeutics Inc. Procoagulant compounds
TW201402611A (zh) * 2012-06-21 2014-01-16 Univ Indiana Res & Tech Corp 具有改變之ｆｃ效應子功能之腸促胰島素受體配體多肽ｆｃ區融合多肽及結合物
US20140302037A1 (en) * 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
CN104558194B (zh) * 2013-10-17 2018-04-27 泰州迈博太科药业有限公司 一类抗CD20-Flex双功能融合蛋白、其制备方法及用途
WO2015095684A1 (en) * 2013-12-20 2015-06-25 Indiana University Research And Technology Corporation Lipidated incretin receptor ligand human immunoglobulin fc-region fusion polypeptides
JP6786392B2 (ja) 2014-01-15 2020-11-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ＦｃＲｎ結合特性が改変され、プロテインＡ結合特性が保持されているＦｃ領域変異体
CN105873948B (zh) 2014-01-15 2021-04-13 豪夫迈·罗氏有限公司 具有修饰的FCRN结合性质的Fc区变体
TW201619188A (zh) 2014-03-05 2016-06-01 優稀美生物醫藥公司 多聚體Ｆｃ蛋白質
WO2015132365A1 (en) 2014-03-05 2015-09-11 Ucb Biopharma Sprl Multimeric fc proteins
US20170029505A1 (en) 2014-04-16 2017-02-02 Ucb Biopharma Sprl Multimeric fc proteins
TN2016000525A1 (en) 2014-05-29 2018-04-04 Macrogenics Inc Tri-specific binding molecules and methods of use thereof
ES2972740T3 (es) 2016-03-02 2024-06-14 Momenta Pharmaceuticals Inc Procedimientos relacionados con construcciones de Fc modificadas genéticamente
IL263213B2 (en) 2016-05-23 2024-05-01 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
EP3565588A4 (en) * 2017-01-06 2020-12-16 Momenta Pharmaceuticals, Inc. COMPOSITIONS AND METHODS RELATING TO MODIFIED FC CONSTRUCTIONS

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008151088A2 (en) * 2007-06-01 2008-12-11 University Of Maryland, Baltimore Immunoglobulin constant region fc receptor binding agents
WO2014031646A2 (en) * 2012-08-20 2014-02-27 Gliknik Inc. Molecules with antigen binding and polyvalent fc gamma receptor binding activity
WO2014060712A1 (en) * 2012-10-17 2014-04-24 Liverpool School Of Tropical Medicine Immunomodulatory proteins
WO2015168643A2 (en) * 2014-05-02 2015-11-05 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc constructs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DAVID N. A. MEKHAIEL ET AL,, POLYMERIC HUMAN FC-FUSION PROTEINS WITH MODIFIED EFFECTOR FUNCTIONS, SUPPLEMENTARY TABLE, 19 October 2012 (2012-10-19) *

Also Published As

Publication number Publication date
JP7045333B2 (ja) 2022-03-31
IL263213B2 (en) 2024-05-01
EP3464376A4 (en) 2020-03-18
BR112018074032A2 (pt) 2019-02-26
IL263213A (en) 2018-12-31
JP7045333B6 (ja) 2022-05-06
US11623964B2 (en) 2023-04-11
KR102635635B1 (ko) 2024-02-14
KR20190026684A (ko) 2019-03-13
EP3484514B1 (en) 2023-12-06
KR20220151025A (ko) 2022-11-11
JP7295301B2 (ja) 2023-06-20
SG11201810465RA (en) 2018-12-28
JP2025026880A (ja) 2025-02-26
KR20190021255A (ko) 2019-03-05
US11155640B2 (en) 2021-10-26
IL309293A (en) 2024-02-01
IL263213B1 (en) 2024-01-01
NZ749292A (en) 2025-08-29
AU2017272111A1 (en) 2019-01-17
SG11201810466PA (en) 2018-12-28
AU2017272109B2 (en) 2024-07-25
NZ749279A (en) 2025-08-29
BR112018074056A2 (pt) 2019-03-06
EP3464376A1 (en) 2019-04-10
US12297291B2 (en) 2025-05-13
WO2017205436A1 (en) 2017-11-30
CN109789203A (zh) 2019-05-21
CA3025306A1 (en) 2017-11-30
US20240067757A1 (en) 2024-02-29
US20220049019A1 (en) 2022-02-17
WO2017205434A1 (en) 2017-11-30
IL263211B1 (en) 2023-05-01
CN109963869A (zh) 2019-07-02
EP3484514A4 (en) 2020-08-12
AU2017272109A1 (en) 2019-01-17
CN116063540A (zh) 2023-05-05
US20190284305A1 (en) 2019-09-19
KR102590061B1 (ko) 2023-10-18
JP2019519528A (ja) 2019-07-11
US20210221917A1 (en) 2021-07-22
SG10202011624SA (en) 2021-01-28
JP2019519527A (ja) 2019-07-11
DK3484514T3 (da) 2024-01-29
JP2022068176A (ja) 2022-05-09
JP2022095685A (ja) 2022-06-28
AU2017272111B2 (en) 2024-05-16
CN118206639A (zh) 2024-06-18
CA3025310A1 (en) 2017-11-30
EP3484514A1 (en) 2019-05-22
IL263211A (en) 2018-12-31
ES2973251T3 (es) 2024-06-19
PL3484514T3 (pl) 2024-04-29
CN109789203B (zh) 2022-08-05
KR102462084B1 (ko) 2022-11-02

Similar Documents

Publication Publication Date Title
US20240067757A1 (en) COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
US12071482B2 (en) Compositions and methods related to engineered Fc constructs
US20210102002A1 (en) HETERODIMERIC IgG-LIKE BISPECIFIC ANTIBODIES
ES3008567T3 (en) Recombinant antibody molecule and its use for target cell restricted t cell activation
US20190352362A1 (en) LAG-3 TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND LAG-3 ANTIGEN BINDING DOMAINS
CN109715663A (zh) 结合生长抑素受体2的异源二聚抗体
KR20180085800A (ko) Cd3 및 psma에 결합하는 이종이합체성 항체
KR102884943B1 (ko) 개선된 항-flt3 항원 결합 단백질
US20220227867A1 (en) ICOS TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND ICOS ANTIGEN BINDING DOMAINS
RU2830982C2 (ru) Улучшенные анти-flt3 антигенсвязывающие белки
HK40105176A (en) Compositions and methods related to engineered fc constructs
TW202140556A (zh) 抗ＮＫｐ３０抗體及使用方法
AU2020344164A1 (en) Recombinant IgG Fc multimers for the treatment of immune complex-mediated kidney disorders
HK1228927A1 (en) Compositions and methods related to engineered fc constructs
HK1228927B (en) Compositions and methods related to engineered fc constructs